Amgen Inc. (NASDAQ:AMGN) Shares Bought by Catalyst Financial Partners LLC

Catalyst Financial Partners LLC grew its stake in Amgen Inc. (NASDAQ:AMGN) by 3.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,153 shares of the medical research company’s stock after purchasing an additional 79 shares during the quarter. Catalyst Financial Partners LLC’s holdings in Amgen were worth $620,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of AMGN. International Assets Investment Management LLC acquired a new stake in shares of Amgen during the 4th quarter valued at approximately $4,589,900,000. Assenagon Asset Management S.A. boosted its holdings in shares of Amgen by 486.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 899,232 shares of the medical research company’s stock valued at $258,997,000 after buying an additional 745,929 shares during the period. abrdn plc grew its position in shares of Amgen by 150.4% during the 4th quarter. abrdn plc now owns 1,043,609 shares of the medical research company’s stock valued at $300,580,000 after buying an additional 626,810 shares during the last quarter. Los Angeles Capital Management LLC raised its stake in Amgen by 111.9% during the fourth quarter. Los Angeles Capital Management LLC now owns 989,061 shares of the medical research company’s stock worth $284,869,000 after acquiring an additional 522,367 shares during the period. Finally, Royal Bank of Canada lifted its holdings in Amgen by 11.4% in the third quarter. Royal Bank of Canada now owns 5,079,677 shares of the medical research company’s stock worth $1,365,213,000 after acquiring an additional 518,689 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research reports. Morgan Stanley increased their price target on Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research report on Friday, May 3rd. William Blair upgraded Amgen from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Royal Bank of Canada lowered their price target on shares of Amgen from $332.00 to $328.00 and set an “outperform” rating for the company in a research report on Friday, May 3rd. Truist Financial reiterated a “buy” rating and issued a $320.00 price objective on shares of Amgen in a research report on Friday, April 12th. Finally, Barclays upgraded shares of Amgen from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $230.00 to $300.00 in a research report on Friday, May 3rd. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $305.65.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the sale, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.69% of the stock is owned by insiders.

Amgen Trading Up 1.8 %

Shares of Amgen stock traded up $5.55 on Thursday, reaching $312.86. 2,920,928 shares of the company were exchanged, compared to its average volume of 2,909,855. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The firm has a market capitalization of $167.83 billion, a price-to-earnings ratio of 44.69, a price-to-earnings-growth ratio of 3.00 and a beta of 0.60. The stock has a fifty day moving average price of $276.24 and a 200-day moving average price of $281.92.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same quarter in the previous year, the business earned $3.98 earnings per share. The firm’s revenue was up 22.0% compared to the same quarter last year. On average, analysts expect that Amgen Inc. will post 19.46 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.88%. Amgen’s dividend payout ratio is 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.